USD 2.59
(11.38%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 136.56 Million USD | -45.46% |
2022 | 250.39 Million USD | 1.63% |
2021 | 246.38 Million USD | 11.16% |
2020 | 221.64 Million USD | 48.68% |
2019 | 149.07 Million USD | 90.43% |
2018 | 78.28 Million USD | 45.98% |
2017 | 53.62 Million USD | 50.43% |
2016 | 35.64 Million USD | -20.16% |
2015 | 44.64 Million USD | -7.22% |
2014 | 48.12 Million USD | -18.22% |
2013 | 58.84 Million USD | -41.14% |
2012 | 99.96 Million USD | -26.45% |
2011 | 135.92 Million USD | -3.81% |
2010 | 141.3 Million USD | 42.68% |
2009 | 99.03 Million USD | 39.72% |
2008 | 70.88 Million USD | -37.57% |
2007 | 113.54 Million USD | 143.34% |
2006 | 46.65 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q3 | 148.18 Million USD | 12.25% |
2024 Q1 | 149.55 Million USD | 9.52% |
2024 Q2 | 132 Million USD | -11.74% |
2023 FY | 136.56 Million USD | -45.46% |
2023 Q1 | 218.06 Million USD | -12.91% |
2023 Q4 | 136.56 Million USD | -11.59% |
2023 Q3 | 154.45 Million USD | -25.3% |
2023 Q2 | 206.76 Million USD | -5.19% |
2022 Q2 | 234.97 Million USD | -0.13% |
2022 Q1 | 235.27 Million USD | -4.51% |
2022 Q4 | 250.39 Million USD | 6.42% |
2022 Q3 | 235.28 Million USD | 0.14% |
2022 FY | 250.39 Million USD | 1.63% |
2021 Q4 | 246.38 Million USD | 8.28% |
2021 FY | 246.38 Million USD | 11.16% |
2021 Q3 | 227.55 Million USD | 7.18% |
2021 Q2 | 212.31 Million USD | 0.07% |
2021 Q1 | 212.17 Million USD | -4.28% |
2020 Q4 | 221.64 Million USD | 60.59% |
2020 FY | 221.64 Million USD | 48.68% |
2020 Q1 | 149.47 Million USD | 0.27% |
2020 Q2 | 141.78 Million USD | -5.14% |
2020 Q3 | 138.01 Million USD | -2.65% |
2019 Q2 | 146.79 Million USD | 45.16% |
2019 FY | 149.07 Million USD | 90.43% |
2019 Q4 | 149.07 Million USD | 1.97% |
2019 Q3 | 146.19 Million USD | -0.41% |
2019 Q1 | 101.12 Million USD | 29.18% |
2018 Q2 | 75.95 Million USD | 70.67% |
2018 FY | 78.28 Million USD | 45.98% |
2018 Q3 | 78.6 Million USD | 3.48% |
2018 Q4 | 78.28 Million USD | -0.4% |
2018 Q1 | 44.5 Million USD | -17.01% |
2017 Q2 | 49.78 Million USD | 62.53% |
2017 Q3 | 44.1 Million USD | -11.42% |
2017 Q1 | 30.63 Million USD | -14.07% |
2017 Q4 | 53.62 Million USD | 21.6% |
2017 FY | 53.62 Million USD | 50.43% |
2016 Q2 | 36.85 Million USD | -5.95% |
2016 FY | 35.64 Million USD | -20.16% |
2016 Q1 | 39.18 Million USD | -12.23% |
2016 Q4 | 35.64 Million USD | -7.43% |
2016 Q3 | 38.51 Million USD | 4.49% |
2015 Q3 | 44.34 Million USD | 25.64% |
2015 Q4 | 44.64 Million USD | 0.69% |
2015 Q2 | 35.29 Million USD | -14.8% |
2015 FY | 44.64 Million USD | -7.22% |
2015 Q1 | 41.42 Million USD | -13.93% |
2014 FY | 48.12 Million USD | -18.22% |
2014 Q4 | 48.12 Million USD | 7.43% |
2014 Q1 | 55.95 Million USD | -4.9% |
2014 Q2 | 45.24 Million USD | -19.15% |
2014 Q3 | 44.79 Million USD | -1.0% |
2013 Q2 | 75.6 Million USD | -19.26% |
2013 Q4 | 58.84 Million USD | -11.43% |
2013 FY | 58.84 Million USD | -41.14% |
2013 Q1 | 93.64 Million USD | -6.33% |
2013 Q3 | 66.43 Million USD | -12.13% |
2012 Q3 | 119.03 Million USD | 1.16% |
2012 Q2 | 117.67 Million USD | -12.58% |
2012 Q1 | 134.6 Million USD | -0.97% |
2012 FY | 99.96 Million USD | -26.45% |
2012 Q4 | 99.96 Million USD | -16.02% |
2011 Q1 | 144.54 Million USD | 2.3% |
2011 Q4 | 135.92 Million USD | -6.02% |
2011 Q3 | 144.62 Million USD | 6.23% |
2011 Q2 | 136.13 Million USD | -5.82% |
2011 FY | 135.92 Million USD | -3.81% |
2010 Q1 | 83.83 Million USD | -15.35% |
2010 Q3 | 148.07 Million USD | 3.06% |
2010 Q4 | 141.3 Million USD | -4.58% |
2010 FY | 141.3 Million USD | 42.68% |
2010 Q2 | 143.67 Million USD | 71.38% |
2009 FY | 99.03 Million USD | 39.72% |
2009 Q4 | 99.03 Million USD | 6.25% |
2009 Q3 | 93.2 Million USD | 0.0% |
2008 FY | 70.88 Million USD | -37.57% |
2008 Q4 | 70.88 Million USD | 0.0% |
2008 Q1 | 95.19 Million USD | 0.0% |
2007 FY | 113.54 Million USD | 143.34% |
2006 FY | 46.65 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 59.929% |
Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 82.162% |
Viridian Therapeutics, Inc. | 490.42 Million USD | 72.155% |
Organovo Holdings, Inc. | 6.34 Million USD | -2050.906% |